Here, we show that CHIP mutation zygosity is an important contributor to risk stratification of CH patients in two large datasets and should be reported in clinical reports of molecular tests noting CHIP in addition to other features with prognostic significance, like the gene mutation and the clonal fraction. This evidence concerns the gene STUB1 and cyclic hematopoiesis.